Abstract:Enteroendocrine L cells and glucagon-like peptide 2 (GLP-2) secretion are activated in the intestinal adaptation process following bowel resection in patients with short bowel syndrome. We hypothesized that enteral activation of Takeda G protein-coupled receptor 5 (TGR5), expressed in enteroendocrine L cells, could augment endogenous GLP-2 secretion and the intestinal adaptation response. Our aim was to assess the efficacy of different TGR5 agonists to stimulate GLP-2 secretion and intestinal adaptation in a piglet short-bowel model. In study 1, parenterally fed neonatal pigs (n = 6/group) were gavaged with vehicle, olive extract (OE: 10 or 50 mg/kg), or ursolic acid (UA; 10 mg/kg), and plasma GLP-2 was measured for 6 h. In study 2, neonatal pigs (n = 6-8/group) were subjected to transection or 80% mid-small intestine resection and, after 2 days, assigned to treatments for 10 days as follows: I) transection + vehicle (sham), 2) resection + vehicle (SBS), 3) resection + 30 mg UA (SBS + UA), and 4) resection + 180 mg/kg OE (SBS + OE.). We measured plasma GLP-2, intestinal histology, cell proliferation, and gene expression, as well as whole body citrulline-arginine kinetics and bile acid profiles. In study 1, GLP-2 secretion was increased by UA and tended to be increased by OE. In study 2, SBS alone, but not additional treatment with either TGR5 agonist, resulted in increased mucosal thickness and crypt cell proliferation in remnant jejunum and ileum sections. SBS increased biliary and ileal concentration of bile acids and expression of inflammatory and farnesoid X receptor target genes, but these measures were suppressed by UA treatment. In conclusion. UA is an effective oral GLP-2 secretagogue in parenterally fed pigs but is not capable of augmenting GLP-2 secretion or the intestinal adaptation response after massive small bowel resection.NEW & NOTEWORTHY Therapeutic activation of endogenous glucagon-like peptide 2 (GLP-2) secretion is a promising strategy to improve intestinal adaptation in patients with short bowel syndrome. This study in neonatal pigs showed that oral supplementation with a selective Takeda G protein-coupled receptor 5 (TGR5) agonist is an effective approach to increase GLP-2 secretion. The results warrant further study to establish a more potent oral TGR5 agonist that can effectively improve intestinal adaptation in pediatric patients with SBS.

Effects of Glucagon-Like Peptide 2 on the Adaptation of Residual Small Bowel in a Rat Model of Short Bowel Syndrome

Effects of Different Growth Factors on Residual Small Bowel Absorption of Glucose in a Rat Model of Short Bowel Syndrome

Effects of glucagon-like peptide-2 on the recovery of structure and function of small intestinal following orthotopic transplantation

An Experimental Study on the Effect of GLP-2 on the Function of Remnant Ileum in Rats with Short Bowel Syndrome

Alteration of glucagon-like peptide-2 (GLP-2) on proliferation of intestinal mucosa in rats following small bowel resection and its time-dependent pattern

Effects of GLP-2 on Mouse Intestinal Mucosal Proliferation after Ischemia/reperfusion Insult

Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis

Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome

Glucagon-Like Peptide-2 Modulates Enteric Paneth Cells Immune Response and Alleviates Gut Inflammation During Intravenous Fluid Infusion in Mice With a Central Catheter

Effects of Recombinant Human Growth Hormone on the Adaptation of the Remnant Small Intestine in Short Bowel Rats

Effects of Glucagon-like Peptide-2 on Morphology, Proliferation and Enzyme Activity of Intestinal Enterocyte Cells of Weaned Piglets in Vitro

[Effect of Glucagon-Like Peptide 2 on the Intestinal Mucosal Immunity and Correlative Cytokines in Mice with Gut Ischemia/reperfusion Injury].

Glucagonlike peptide 2 protects intestinal barrier in severe acute pancreatitis through regulating intestinal epithelial cell proliferation and apoptosis.

Differential Action Of Tgr5 Agonists On Glp-2 Secretion And Promotion Of Intestinal Adaptation In A Piglet Short Bowel Model

A dose-equivalent comparison of the effects of continuous subcutaneous glucagon-like peptide 2 (GLP-2) infusions versus meal related GLP-2 injections in the treatment of short bowel syndrome (SBS) patients

[Effect of Glutamine and Growth Hormone on Adaptation in Short Bowel Syndrome].

Effects of Glucagon-like Peptide 2 (GLP-2) on Morphology Proliferation Function and Enzyme Activity of Small Intestinal Epithelial Cell of Weaning Pig in Vitro

Colonic Adaption in Short Bowel Syndrome

The Optimal Time of GLP-2 Intervene for Early Intestinal Rehabilitation in a Rat Model of Massive Bowel Resection

The protective and anti-inflammatory effects of a modified glucagon-like peptide-2 dimer in inflammatory bowel disease.

Glp-2 Prevents Intestinal Mucosal Atrophy And Improves Tissue Antioxidant Capacity In A Mouse Model Of Total Parenteral Nutrition